И. В. Терешкина
Russian Cancer Research Center NN Blokhin · 19 works · 65 citations · h-index 4
Top works
- Matrix Metalloproteinases 2, 7, and 9 in Tumors and Sera of Patients with Breast Cancer
- Matrix Metalloproteinases 2, 7, and 9 and Tissue Inhibitor of Metalloproteinases-1 in Tumors and Serum of Patients with Ovarian Neoplasms
- Matrix metalloproteinases: structure, functions and genetic polymorphism
- Relationship between the Expression of VEGF Signal Components and Matrix Metalloproteinases in Ovarian Tumors
- Immunological Peculiarities of CD-56-Positive Serous Ovarian Adenocarcinoma
- Soluble forms of immune checkpoints in ovarian cancer
- THE CONTENT OF MATRIX METALLOPROTEINASE-7 IN BLOOD SERUM AND TUMOR IN PATIENTS WITH OVARIAN CANCER
- The role of mRNA in the biology and manifestation of ovarian malignant tumors
- Содержание матриксных металлопротеиназ 2; 7 и 9 в опухолях и сыворотке крови больных раком молочной железы
- Comparative analysis of serum and tumor vascular endothelial growth factor, insulin-like growth factor 1, matrix metalloproteinase 7 levels in patients with ovarian cancer
- Фактор роста эндотелия сосудов в сыворотке крови больных раком молочной железы
- Матриксные металлопротеиназы: структура, функции и генетический полиморфизм
- P423 State of lipid preoxidation and antioxidant defense system in patients with autoimmune miscarriages after ozone therapy
- CLINICAL CHARACTERISTICS OF MATRIX METALLOPROTEINASES 2, 7, 9 AND THEIR TISSUE INHIBITORS 1 AND 2 TYPE IN THE BLOOD SERUM OF PATIENTS WITH CANCER ENDOMETRY
- Рак молочной железы и инсулиноподобные факторы роста
- Содержание и ДНК-связывающая активность ядерного транскрипционного фактора NF-kB в опухолях больных раком молочной железы
- Clinical prospects of insulin-like growth factors and IGF binding proteins study in blood serum of ovarian cancer patients
- Клинические перспективы исследования инсулиноподобных факторов роста и ИФР-связывающих белков в сыворотке крови больных раком яичника
- Current concepts on the role of matrix metalloproteinases and their tissue inhibitors in the clinical course and prognosis of ovarian cancer